Admission heart rate predicts mortality following primary percutaneous coronary intervention for st-elevation myocardial infarction: An observational study

Cardiovascular Therapeutics

Volumn 31, Issue 6, 2013, Pages 363-369

  Noman, Awsan ^a   Balasubramaniam, Karthik ^b   Das, Rajiv ^a   Ang, Donald ^a   Kunadian, Vijay ^a,b   Ivanauskiene, Taida ^a   Zaman, Azfar G ^a,b  

^a FREEMAN HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Beta blocker; Heart rate; Mortality; Primary percutaneous coronary intervention; ST elevation myocardial infarction

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; HEMOGLOBIN;

ADULT; AGE; ARTICLE; BLOOD CLOT LYSIS; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART INFARCTION; HEART RATE; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; POST TREATMENT SURVIVAL; PREDICTIVE VALUE; PRIMARY PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK REDUCTION; SEX DIFFERENCE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTOLIC BLOOD PRESSURE; TIME TO TREATMENT; VASCULAR DISEASE;

BETA BLOCKER; HEART RATE; MORTALITY; PRIMARY PERCUTANEOUS CORONARY INTERVENTION; ST-ELEVATION MYOCARDIAL INFARCTION;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; RETROSPECTIVE STUDIES;

EID: 84887330610     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12031     Document Type: Article

References (23)

1. Fox K, Borer JS, Camm AJ, et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007;50:823-830.
2. Diaz A, Bourassa MG, Guertin MC, et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005;26:967-974.
3. Kolloch R, Legler UF, Champion A, et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: Findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J 2008;29:1327-1334.
4. Fosbol EL, Seibaek M, Brendorp B, et al. Long-term prognostic importance of resting heart rate in patients with left ventricular dysfunction in connection with either heart failure or myocardial infarction: The DIAMOND study. Int J Cardiol 2010;140:279-286.
5. Fox K, Ford I, Steg PG, et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A subgroup analysis of a randomised controlled trial. Lancet 2008;372:817-821.
6. Bohm M, Cotton D, Foster L, et al. Impact of resting heart rate on mortality, disability and cognitive decline in patients after ischaemic stroke. Eur Heart J 2012;33:2804-2812.
7. Okin PM, Kjeldsen SE, Julius S, et al. All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. Eur Heart J 2010;31:2271-2279.
8. Julius S, Palatini P, Kjeldsen SE, et al. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol 2012;109:685-692.
9. Jouven X, Empana JP, Escolano S, et al. Relation of heart rate at rest and long-term (>20 years) death rate in initially healthy middle-aged men. Am J Cardiol 2009;103:279-283.
10. Kushner FG, Hand M, Smith SC Jr., et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009;120:2271-2306.
11. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J 2008;29:2909-2945.
12. Antoni ML, Boden H, Delgado V, et al. Relationship between discharge heart rate and mortality in patients after acute myocardial infarction treated with primary percutaneous coronary intervention. Eur Heart J 2012;33:96-102.
13. Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: Estimating the risk of 6-month postdischarge death in an international registry. JAMA 2004;291:2727-2733.
14. Stebbins A, Mehta RH, Armstrong PW, et al. A model for predicting mortality in acute ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: Results from the assessment of pexelizumab in acute myocardial infarction trial. Circ Cardiovasc Interv 2010;3:414-422.
15. Parodi G, Bellandi B, Valenti R, et al. Heart rate as an independent prognostic risk factor in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Atherosclerosis 2010;211:255-259.
16. Morrow DA, Antman EM, Parsons L, et al. Application of the TIMI risk score for ST-elevation MI in the national registry of myocardial infarction 3. JAMA 2001;286:1356-1359.
17. Heggunje PS, Harjai KJ, Stone GW, et al. Procedural success versus clinical risk status in determining discharge of patients after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 2004;44:1400-1407.
18. Gundersen T, Grottum P, Pedersen T, et al. Effect of timolol on mortality and reinfarction after acute myocardial infarction: Prognostic importance of heart rate at rest. Am J Cardiol 1986;58:20-24.
19. Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 1986;57:43F-49F.
20. Cucherat M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: A meta-regression of randomized clinical trials. Eur Heart J 2007;28:3012-3019.
21. Panza JA, Diodati JG, Callahan TS, et al. Role of increases in heart rate in determining the occurrence and frequency of myocardial ischemia during daily life in patients with stable coronary artery disease. J Am Coll Cardiol 1992;20:1092-1098.
22. Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A randomised, double-blind, placebo-controlled trial. Lancet 2008;372:807-816.
23. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study. Lancet 2010;376:875-885.